Additional Supporting Information may be found in the online version of this article.

STEM_1386_sm_SuppTab1.pdf11KSupporting Information
STEM_1386_sm_SuppFig.tiff1720KSupplemental Figure Legends: (A) Frequency of CD3+ CD4 and CD8 double negative (DN) T-cells in MSC treated (green) and placebo (red) treated patients at day +30, +90 and +180 post infusion as well as 10 healthy donors. Horizontal line depicts arithmetic mean and the grey area range of values (5th- 95th percentile) of the healthy donors. (B) The fraction of CD62L+ regulatory T-cells (Treg) was evaluated in both groups as well as in healthy donors (n=10) (HD/blue). (C and D) In both myeloid DCs (mDCs) (panel C) and plasmacytoid DCs (pDCs) (panel D), the expression density of the maturation marker CD83 and the co-stimulatory molecule CD86 was studied. (E) The frequency of CD14+ monocytes was evaluated as shown in the representative FACS analysis. (F) Level of HLA-DR surface density in CD14+ monocytes. (G) Activation level of NK-cells was studied by quantifying the activation markers CD25, CD69, and HLA-DR on NK-cells. Abbreviations: PBMCs, peripheral blood mononuclear cells, MFI, mean fluorescence index.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.